MASH innovator drug partnerships surge over $2.5 bn in 2024YTD: GlobalData
MASH drugs secured over $5.7 billion in total partnership deal value from 2018 to 2024YTD, where 2024YTD is already the top year…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
NASH
Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData
In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the…
Lupin, Zydus sign licensing pact to co-market Saroglitazar Mg for chronic liver diseases in India
In 2020, Saroglitazar Mg received approval for the treatment of NASH and NAFLD
HepaStem seems most promising pipeline agent for decompensated cirrhosis due to NASH: GlobalData
HepaStem is a stem cell therapy consisting of liver-derived mesenchymal stem cells (MSC) that addresses different components of…
NASH market holds enormous untapped potential: GlobalData
Currently, Madrigal’s resmetirom (selective thyroid hormone receptor-β agonist; THR-Beta agonist) will most likely be the first…
Zydus announces Phase IV EVIDENCES-XI trial to generate RWE of Saroglitazar Mg in NAFLD patients…
Phase IV EVIDENCES- XI trial will enroll approximately 1500 NAFLD patients with comorbidities
Gilead, Novo Nordisk expand NASH clinical collaboration
Triple combination regimen to be investigated in new Phase 2b study in NASH patients with cirrhosis
Zydus gets DCGI approval for Saroglitazar Mg to treat non-alcoholic fatty liver disease
Saroglitazar Mg is already approved for the treatment of type-2 diabetes and NASH
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData
The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029
Gannex receives US IND Approval for NASH drug candidate, an FXR agonist
In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis